A registry started by KPWHRI last year has sped up studies needed to protect the world against the novel coronavirus.
Now more than ever we can benefit from studies embedded in health-care systems to answer common clinical questions.
Lisa A. Jackson, MD, MPH, is leading a study of pneumococcal vaccine in older adults at six Vaccine and Treatment Evaluation Units (VTEUs) across the nation, including at Group Health. Dr. Jackson, a senior investigator at Group Health Research Institute, leads the Seattle-area VTEU. Dr. Jackson and her colleagues plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier-generation vaccine against pneumonia and other pneumococcal diseases.